



Investor News no. 3/2007

To OMX Nordic Exchange Copenhagen

Copenhagen, November 27, 2007

## **Investor News: Curalogic has presented at the Piper Jaffray Conference in New York**

Curalogic A/S (OMX: CUR) participates in Piper Jaffray 19th Annual Healthcare Conference November 27-29, 2007 in New York.

The presentation was held by Peter Moldt, Ph.D., President and Chief Executive Officer of Curalogic and was scheduled for:

**Tuesday 8:30 AM local time on November 27, 2007.**

The PowerPoint presentation is available at [www.curalogic.com](http://www.curalogic.com).

Yours sincerely

Curalogic A/S

### **For additional information, please contact:**

Peter Moldt, President and CEO

Tel +45 99 99 24 00, mobile +45 2625 0422

Helle Busck Fensvig, EVP and CFO

Tel +45 99 99 24 00, mobile +45 2070 5537

### **About Curalogic**

Curalogic is a Danish biopharmaceutical company listed on the OMX Nordic Exchange (CUR.CO). Curalogic develops innovative pharmaceuticals for the treatment of allergy. By combining the best of two worlds - the efficacy of immunotherapy combined with the safety and patient convenience of symptomatic treatments – Curalogic aims to develop a novel and user-friendly form of allergy treatment, and make it the preferred type of allergy treatment among patients. Curalogic has a broad and mature pipeline with a product for treatment of ragweed allergy in Phase III, a product for treatment of grass allergy ready for Phase III, a product for treatment of cat allergy in Phase II and a product for treatment of house dust mite allergy preparing for clinical trials.